Belinda S Hall Selected Research

mycolactone

1/2022	Aberrant stromal tissue factor localisation and mycolactone-driven vascular dysfunction, exacerbated by IL-1β, are linked to fibrin formation in Buruli ulcer lesions.
1/2022	Inhibition of the SEC61 translocon by mycolactone induces a protective autophagic response controlled by EIF2S1-dependent translation that does not require ULK1 activity.
1/2021	The One That Got Away: How Macrophage-Derived IL-1β Escapes the Mycolactone-Dependent Sec61 Blockade in Buruli Ulcer.
1/2018	Inhibition of Sec61-dependent translocation by mycolactone uncouples the integrated stress response from ER stress, driving cytotoxicity via translational activation of ATF4.
7/2015	Mycolactone-Dependent Depletion of Endothelial Cell Thrombomodulin Is Strongly Associated with Fibrin Deposition in Buruli Ulcer Lesions.
4/2014	The pathogenic mechanism of the Mycobacterium ulcerans virulence factor, mycolactone, depends on blockade of protein translocation into the ER.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Belinda S Hall Research Topics

Disease

6	Buruli Ulcer 01/2022 - 04/2014
6	Infections 01/2022 - 10/2010
4	Necrosis 01/2022 - 04/2014
4	Chagas Disease (American Trypanosomiasis) 07/2012 - 01/2011
3	African Trypanosomiasis (Nagana) 04/2013 - 01/2011
2	Ischemia 01/2022 - 07/2015
2	Neglected Diseases 01/2022 - 01/2018
2	Hypersensitivity (Allergy) 04/2013 - 03/2010
1	Purpura 07/2015
1	Leishmaniasis 10/2013
1	Parasitic Diseases (Parasitic Disease) 01/2012

Drug/Important Bio-Agent (IBA)

6	mycolactoneIBA 01/2022 - 04/2014
5	ProdrugsIBA 10/2013 - 01/2011
4	ExotoxinsIBA 01/2022 - 07/2015
3	NifurtimoxIBA 04/2013 - 01/2011
3	benzonidazole (benznidazole)IBA 07/2012 - 01/2011
2	FibrinIBA 01/2022 - 07/2015
2	Virulence Factors (Pathogenicity Factors)IBA 01/2018 - 04/2014
2	EnzymesIBA 04/2013 - 03/2010
2	Pharmaceutical PreparationsIBA 07/2012 - 10/2010
1	Phosphates (Orthophosphate)IBA 01/2022
1	bafilomycin A1IBA 01/2022
1	phosphatidylinositol 3-phosphateIBA 01/2022
1	Blood Proteins (Serum Proteins)IBA 01/2022
1	CalciumIBA 01/2022
1	Carrier Proteins (Binding Protein)IBA 01/2022
1	Chloroquine (Aralen)FDA LinkGeneric 01/2022
1	Dimethyl Sulfoxide (DMSO)FDA LinkGeneric 01/2022
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2022
1	paraform (paraformaldehyde)IBA 01/2022
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2022
1	Phosphotransferases (Kinase)IBA 01/2022
1	Thromboplastin (Tissue Factor)IBA 01/2022
1	UbiquitinIBA 01/2022
1	Prokaryotic Initiation Factor-2IBA 01/2022
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2022
1	Green Fluorescent ProteinsIBA 01/2022
1	Activating Transcription Factor 4IBA 01/2022
1	ThrombomodulinIBA 07/2015
1	AnticoagulantsIBA 07/2015
1	MacrolidesIBA 07/2015
1	CytokinesIBA 04/2014
1	NitroreductasesIBA 10/2013
1	NADH dehydrogenase (quinone)IBA 10/2013
1	Flavin Mononucleotide (FMN)IBA 10/2013
1	Eflornithine (Ornidyl)FDA Link 04/2013
1	Antiparasitic Agents (Antiparasitics)IBA 04/2013
1	azomycinIBA 01/2012
1	fexinidazoleIBA 01/2011
1	LuciferasesIBA 10/2010

Therapy/Procedure

2	Therapeutics 04/2013 - 04/2011